Skip to main content
AMRX
NASDAQ Life Sciences

Amneal to Acquire Kashiv BioSciences, Reports Strong Q1 Results & Raises Full-Year Guidance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$12.82
Mkt Cap
$4.09B
52W Low
$7.02
52W High
$15.42
52W Position info
83% above low
Off High info
17% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

AMRX sits 83% above its 52-week low of $7.02.

Summary

Amneal Pharmaceuticals announced a definitive agreement to acquire Kashiv BioSciences, a strategic move to become a global biosimilars leader, alongside reporting strong preliminary Q1 2026 financial results and raising its full-year guidance.


Key Events · M&A and Partnerships · AMRX

  • Acquisition Agreement

    Amneal Pharmaceuticals entered into a definitive agreement to acquire 100% ownership of Kashiv BioSciences, LLC, a vertically integrated biopharmaceutical company.

  • Strategic Rationale

    The acquisition is expected to create a fully integrated global biosimilars leader, diversify Amneal's business, and position it for a strong cadence of new biosimilar launches, adding over 600 skilled individuals to its team.

  • Preliminary Q1 2026 Financial Results

    The company reported strong preliminary first quarter 2026 results, including net revenue of $723 million, adjusted EBITDA of $202 million, and adjusted EPS of $0.27.

  • Raised Full-Year 2026 Guidance

    Amneal increased its full-year 2026 guidance, now expecting $3.05-$3.15 billion in net revenue and $740-$770 million in adjusted EBITDA.


Analysis · AMRX · Life Sciences

This DEFA14A filing provides additional soliciting materials related to Amneal's definitive agreement to acquire Kashiv BioSciences, a vertically integrated biopharmaceutical company. This acquisition is a significant strategic move, positioning Amneal as a global biosimilars leader with an expanded portfolio and pipeline. The filing also includes highly positive preliminary Q1 2026 financial results and an upward revision of full-year 2026 guidance, indicating strong operational performance and confidence in future growth. The combination of a major strategic acquisition and robust financial updates makes this a critical market-moving event.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 49.5% of the 210 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AMRX was trading at $12.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1B. The 52-week trading range was $7.02 to $15.42. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AMRX - Latest Insights

AMRX
Nov 09, 2026, 4:21 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $21.28
Real-time Price: $21.38 info
Change: +$0.100 (+0.47%) info
Market Cap: $7.449B info
AMRX
Nov 03, 2026, 6:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $20.23
Real-time Price: $21.38 info
Change: +$1.15 (+6%) info
Market Cap: $7.449B info
AMRX
Nov 03, 2026, 6:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $20.20
Real-time Price: $21.38 info
Change: +$1.18 (+6%) info
Market Cap: $7.449B info
AMRX
Oct 23, 2026, 4:05 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $20.38
Real-time Price: $21.38 info
Change: +$1.00 (+5%) info
Market Cap: $7.449B info
AMRX
Sep 18, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $18.71
Real-time Price: $21.38 info
Change: +$2.67 (+14%) info
Market Cap: $7.449B info